凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2018年第三季度报告

公告日期 2018-10-15
股票简称:梅花生物 股票代码:600873
                        2018 年第三季度报告



公司代码:600873                              公司简称:梅花生物




            梅花生物科技集团股份有限公司

                   2018 年第三季度报告




                              1 / 19
                                                       2018 年第三季度报告




                                                            目录
一、重要提示.........................................................................................................................3

二、公司基本情况.................................................................................................................3

三、重要事项.........................................................................................................................6

四、附录.................................................................................................................................8




                                                                2 / 19
                                       2018 年第三季度报告




  一、 重要提示


  1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,

         不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

  1.2 公司全体董事出席董事会审议季度报告。

  1.3 公司负责人王爱军、主管会计工作负责人王威及会计机构负责人(会计主管人员)王爱玲保

         证季度报告中财务报表的真实、准确、完整。

  1.4 本公司第三季度报告未经审计。



  二、 公司基本情况


  2.1 主要财务数据
                                                                            单位:元 币种:人民币
                                                                                      本报告期末比上年度
                                    本报告期末                  上年度末
                                                                                          末增减(%)

总资产                              18,266,252,123.81            17,101,915,003.75                     6.81

归属于上市公司股东的净资产           8,829,092,012.50             9,105,157,993.88                    -3.03

                                  年初至报告期末          上年初至上年报告期末
                                                                                      比上年同期增减(%)
                                    (1-9 月)                 (1-9 月)

经营活动产生的现金流量净额           2,131,753,036.17             1,269,717,666.73                    67.89

                                  年初至报告期末          上年初至上年报告期末         比上年同期增减

                                    (1-9 月)                 (1-9 月)                   (%)

营业收入                             9,300,291,532.84             7,940,373,793.70                    17.13

归属于上市公司股东的净利润             729,301,001.89              695,327,136.24                      4.89

归属于上市公司股东的扣除非经常
                                       643,804,257.54              543,967,368.46                     18.35
性损益的净利润

加权平均净资产收益率(%)                          7.99                        7.53     增加 0.46 个百分点

基本每股收益(元/股)                              0.23                        0.22                    4.55

稀释每股收益(元/股)                              0.23                        0.22                    4.55


  非经常性损益项目和金额
  √适用 □不适用
                                                                            单位:元 币种:人民币
                                                 3 / 19
                                         2018 年第三季度报告



                                                               本期金额        年初至报告期       说明
                           项目
                                                           (7-9 月)         末金额(1-9 月)

非流动资产处置损益                                             -2,714,753.32     -4,885,937.15

越权审批,或无正式批准文件,或偶发性的税收返还、减免

计入当期损益的政府补助,但与公司正常经营业务密切相关,

符合国家政策规定、按照一定标准定额或定量持续享受的政府         3,128,072.95     35,975,817.07

补助除外

计入当期损益的对非金融企业收取的资金占用费

企业取得子公司、联营企业及合营企业的投资成本小于取得投

资时应享有被投资单位可辨认净资产公允价值产生的收益

非货币性资产交换损益

委托他人投资或管理资产的损益                               13,306,357.01        43,645,463.66

因不可抗力因素,如遭受自然灾害而计提的各项资产减值准备

债务重组损益

企业重组费用,如安置职工的支出、整合费用等

交易价格显失公允的交易产生的超过公允价值部分的损益

同一控制下企业合并产生的子公司期初至合并日的当期净损



与公司正常经营业务无关的或有事项产生的损益

除同公司正常经营业务相关的有效套期保值业务外,持有交易

性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                           22,202,500.00         20,243,222.20
处置交易性金融资产、交易性金融负债和可供出售金融资产取

得的投资收益

单独进行减值测试的应收款项减值准备转回

对外委托贷款取得的损益

采用公允价值模式进行后续计量的投资性房地产公允价值变

动产生的损益

根据税收、会计等法律、法规的要求对当期损益进行一次性调

整对当期损益的影响

受托经营取得的托管费收入

除上述各项之外的其他营业外收入和支出                           5,487,964.96       5,918,562.94

其他符合非经常性损益定义的损益项目

少数股东权益影响额(税后)                                      -189,308.87        -220,300.16

所得税影响额                                                   -6,950,355.70    -15,180,084.21

                           合计                            34,270,477.03         85,496,744.35




                                               4 / 19
                                                2018 年第三季度报告




   2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                             单位:股
股东总数(户)                                                                                                    157,471
                                                   前十名股东持股情况
         股东名称           期末持股数                   持有有限售条         质押或冻结情况
                                            比例(%)                                                            股东性质
         (全称)               量                        件股份数量      股份状态              数量
孟庆山                      854,103,033      27.48             0            质押             240,000,000      境内自然人
胡继军                      248,469,341       7.99             0            质押             94,162,000       境内自然人
中国证券金融股份有限公司    151,485,962       4.87             0            未知                               国有法人
杨维永                      78,810,526        2.54             0            质押             50,328,300       境内自然人
王爱军                      71,316,274        2.29             0            无                   0            境内自然人
梁宇博                      54,868,518        1.77         1,200,000        无                   0            境内自然人
全国社保基金四一四组合      31,509,571        1.01             0            未知                                 其他
梅花生物科技集团股份有限
公司-2017 年第一期员工持   29,007,028        0.93             0            无                   0               其他
股计划
何君                        23,449,758        0.75             0            无                   0            境内自然人
中央汇金资产管理有限责任
                            19,292,700        0.62             0            未知                               国有法人
公司
                                           前十名无限售条件股东持股情况
                                                                                            股份种类及数量
              股东名称                     持有无限售条件流通股的数量
                                                                                     种类                     数量
孟庆山                                               854,103,033              人民币普通股                 854,103,033
胡继军                                               248,469,341              人民币普通股                 248,469,341
中国证券金融股份有限公司                             151,485,962              人民币普通股                 151,485,962
杨维永                                                78,810,526              人民币普通股                 78,810,526
王爱军                                                71,316,274              人民币普通股                 71,316,274
梁宇博                                                53,668,518              人民币普通股                 53,668,518
全国社保基金四一四组合                                31,509,571              人民币普通股                 31,509,571
梅花生物科技集团股份有限公司-2017
                                                      29,007,028              人民币普通股                 29,007,028
年第一期员工持股计划
何君                                                  23,449,758              人民币普通股                 23,449,758
中央汇金资产管理有限责任公司                          19,292,700              人民币普通股                 19,292,700
上述股东关联关系或一致行动的说明          上述股东中,孟庆山、王爱军、何君为一致行动人,其他股东未知其一致行动
                                          关系。
   备注:截止 2018 年 6 月 30 日,公司董事、副总经理梁宇博先生持有公司 53,668,518 股股份,全
   部为无限售条件流通股。公司于 2018 年 7 月实施了限制性股票激励计划,梁宇博先生认购限制性
   股票 120 万股,因此截止本报告期末梁宇博先生持股 54,868,518 股,其中 120 万股为有限售条件
   股份,53,668,518 股为无限售条件流通股。




                                                         5 / 19
                                                      2018 年第三季度报告




           2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情

                 况表
           □适用 √不适用



           三、 重要事项


           3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
           √适用 □不适用
           资产负债表:                                                                               单位:万元
         项目           本报告期末   上年度期末     增减额        增减幅度%                       差异说明
以公允价值计量且其
                                                                               主要系本期新增远期购汇业务期末未结,将其按照
变动计入当期损益的       3,345.00      790.80      2,554.20         322.99
                                                                               公允价值进行计量损益所致
金融资产
                                                                               主要系本期投资银行理财增加所致以及待抵扣税金
其他流动资产            71,004.91    22,402.53    48,602.38         216.95
                                                                               增加所致
                                                                               主要系本期子公司新疆农业为推动公司原材料供应
长期股权投资             2,728.14      981.21      1,746.93         178.04
                                                                               链的转型升级投资设立参股公司所致
在建工程                107,037.55   28,380.89    78,656.66         277.15     主要系本期子公司吉林梅花项目投入增加所致
无形资产                123,669.34   82,387.33    41,282.02          50.11     主要系本期子公司吉林梅花新增土地使用权所致
长期待摊费用             2,643.18     1,209.64     1,433.53         118.51     主要系本期新增银团贷款产生银团前端费用所致
                                                                               主要系本期子公司吉林梅花收到与资产相关的政府
递延所得税资产           6,152.45     1,254.45     4,898.00         390.45
                                                                               补助对应产生递延所得税所致
其他非流动资产          47,642.31    10,082.33    37,559.98         372.53     主要系本期子公司吉林梅花预付工程款增加所致
                                                                               主要系本期增加银行承兑汇票以及子公司吉林梅花
应付票据及应付账款      119,198.71   67,912.28    51,286.43          75.52
                                                                               应付货款增加所致
预收款项                42,936.43    31,930.88    11,005.55          34.47     主要系本期预收客户货款增加所致
                                                                               主要系本公司分红款部分未发放、公司债应付利息
其他应付款              70,020.21    28,432.32    41,587.89         146.27
                                                                               增加以及新增限制性股票回购义务所致
长期借款                127,391.00   30,000.00    97,391.00         324.64     本期新增银团贷款所致
应付债券                149,758.78   299,099.41   -149,340.63       -49.93     主要系本期 15 梅花 01 期公司债到期偿还所致
长期应付款               4,388.64     6,715.94     -2,327.31        -34.65     主要系本期公司按约支付专利款项所致
                                                                               主要系本期子公司吉林梅花收到与资产相关的政府
递延收益                48,341.81     9,079.15    39,262.66         432.45
                                                                               补助所致
                                                                               主要系本期实施股权激励计划,员工认购公司股份
库存股                   7,344.94    19,999.99    -12,655.05        -63.28
                                                                               所致


           利润表:                                                                               单位:万元
         项目            本报告期     上年同期     增减额        增减幅度%                        差异说明
                                                                              主要系本期新增水资源税、环保税以及城建及附加税
税金及附加               16,271.93    11,193.67   5,078.26         45.37
                                                                              增加所致

                                                                6 / 19
                                                         2018 年第三季度报告


资产减值损失           161.25         1,156.35        -995.10          -86.05      主要系本期计提坏账准备减少所致
其他收益              3,597.58        11,572.97       -7,975.38        -68.91      主要系本期收到的政府补贴减少所致
投资收益              3,781.60        6,036.63        -2,255.03        -37.36      主要系本期银行理财收益减少所致
                                                                                   主要系本期新增远期购汇业务期末未结,将其按照公
公允价值变动收益      2,554.20         519.59         2,034.61         391.58
                                                                                   允价值进行计量损益所致
资产处置收益           -53.43          176.62         -230.05          -130.25     主要系本期固定资产处置收益减少所致
营业外支出             677.60         1,416.45        -738.85          -52.16      主要系本期捐赠支出减少所致
           现金流量表:                                                                                 单位:万元
             项目                本报告期        上年同期          增减额        增减幅度%                  差异说明
                                                                                             主要系本期随着销售收入的增加销售回款
经营活动产生的现金流量净额      213,175.30      126,971.77        86,203.54        67.89
                                                                                             增加所致
                                                                                             主要系本期子公司吉林梅花新增土地使用
投资活动产生的现金流量净额      -164,174.33      -35,875.50      -128,298.84      -357.62
                                                                                             权以及项目工程款项支出增加所致
筹资活动产生的现金流量净额      -101,998.43      -16,795.40       -85,203.04      -507.30    主要系本期偿还 15 亿公司债所致




           3.2 重要事项进展情况及其影响和解决方案的分析说明
           √适用 □不适用
                (1)惠尔股份新三板摘牌情况
                公司持有新疆慧尔农业集团股份有限公司(简称“惠尔股份”)600万股股份,占惠尔股份股
           本总数的10.345%。根据惠尔股份2018年8月14日、2018年9月21日发布的相关公告,惠尔股份终
           止首次公开发行股票并上市的申请并撤回申请文件,并自2018年9月21日起终止在全国中小企业股
           份转让系统挂牌。
                (2)限制性股票激励授予事项进展情况
                2018年6月20日,公司召开了2017年年度股东大会,会上审议通过《关于公司<2018年限制性
           股票激励计划(草案)>及其摘要的议案》、《关于公司<2018年限制性股票激励计划实施考核管
           理办法>的议案》、《关于提请股东大会授权董事会办理公司2018年限制性股票激励计划相关事
           宜的议案》。随后,公司召开第八届董事会第十七次会议和公司第八届监事会第九次会议,审议
           通过了《关于向激励对象授予限制性股票的议案》。
                在确定授予日后的资金缴纳、股份登记过程中,有2名激励对象因被免职放弃认购其对应的
           5.1565万股股票,因而公司本次限制性股票实际授予对象为109人,实际授予数量为3,448.33万股,
           占授予前公司总股本310,822.6603万股的1.1094%,该部分股份已于2018年7月17日完成登记工作。
                2018年限制性股票激励计划确定授予日后的资金缴纳、股份登记过程中,因2名激励对象被免
           职放弃认购,因此其对应的51,565股股票已做注销处理,2018年7月18日注销完成后公司总股本由
           3,108,226,603股变更为3,108,175,038股。目前股本变动涉及到的工商登记手续尚未办理。
                (3)西藏银行股份有限公司2017年度分红事宜进展情况
                经西藏银行股份有限公司(简称“西藏银行”)2017年年度股东大会审议通过,西藏银行2017
           年度利润分配方案为每10股转增1股,每10股分配利润0.2元(含税)。利润分配方案实施完成后
           公司将获得现金红利256万元(含税),持有西藏银行的股份数将由12,800万股变为14,080万股。
                (4)新建40万吨赖氨酸项目进展情况
                                                                   7 / 19
                                         2018 年第三季度报告



       公司在吉林省白城市建立了第三生产基地,报告期内白城基地的建设工作按照既定计划紧锣
  密鼓的推进,一期将建成年产40万吨赖氨酸产能,目前项目建设进展顺利,计划在2018年四季度
  建成试车。

  3.3 报告期内超期未履行完毕的承诺事项
  □适用 √不适用

  3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警

       示及原因说明
  □适用 √不适用



                                                   公司名称          梅花生物科技集团股份有限公司
                                                  法定代表人                      王爱军
                                                     日期                   2018 年 10 月 15 日




  四、 附录


  4.1 财务报表
                                      合并资产负债表
                                     2018 年 9 月 30 日
  编制单位:梅花生物科技集团股份有限公司

                                                    单位:元 币种:人民币 审计类型:未经审计
                      项目                               期末余额                       年初余额
流动资产:
 货币资金                                                      1,930,336,135.03            2,277,116,405.54
 结算备付金
 拆出资金
 以公允价值计量且其变动计入当期损益的金融资产                    33,450,000.00                    7,908,000.00
 衍生金融资产
 应收票据及应收账款                                             562,308,484.27               584,764,782.18
 其中:应收票据                                                  61,339,204.82               109,191,343.59
       应收账款                                                 500,969,279.45               475,573,438.59
 预付款项                                                       428,267,055.78               560,312,842.25
 应收保费
 应收分保账款
 应收分保合同准备金

                                                8 / 19
                                         2018 年第三季度报告



 其他应收款                                                     167,389,330.49      142,726,555.99
 其中:应收利息
        应收股利
 买入返售金融资产
 存货                                                           863,351,414.89      995,023,260.79
 持有待售资产
 一年内到期的非流动资产
 其他流动资产                                                   710,049,095.19      224,025,301.93
   流动资产合计                                                4,695,151,515.65    4,791,877,148.68
非流动资产:
 发放贷款和垫款
 可供出售金融资产                                               665,657,354.59      563,919,754.00
 持有至到期投资
 长期应收款
 长期股权投资                                                    27,281,413.77         9,812,073.15
 投资性房地产
 固定资产                                                      9,863,539,817.05   10,359,985,909.93
 在建工程                                                      1,070,375,541.44     283,808,946.15
 生产性生物资产
 油气资产
 无形资产                                                      1,236,693,442.82     823,873,279.30
 开发支出
 商誉                                                           143,173,700.39      143,173,700.39
 长期待摊费用                                                    26,431,752.03       12,096,408.99
 递延所得税资产                                                  61,524,480.22       12,544,511.15
 其他非流动资产                                                 476,423,105.85      100,823,272.01
   非流动资产合计                                          13,571,100,608.16      12,310,037,855.07
     资产总计                                              18,266,252,123.81      17,101,915,003.75
流动负债:
 短期借款                                                      3,335,072,000.00    2,768,494,000.00
 向中央银行借款
 吸收存款及同业存放
 拆入资金
 以公允价值计量且其变动计入当期损益的金融负债
 衍生金融负债
 应付票据及应付账款                                            1,191,987,072.53     679,122,790.43
 预收款项                                                       429,364,309.15      319,308,817.06
 卖出回购金融资产款
 应付手续费及佣金
 应付职工薪酬                                                    97,760,346.34       94,927,531.20
 应交税费                                                       125,776,457.90      146,396,845.03
 其他应付款                                                     700,202,120.94      284,323,177.00

                                                9 / 19
                                          2018 年第三季度报告



 其中:应付利息                                                   78,796,526.60             58,469,367.30
       应付股利                                                  326,493,672.87             12,037,536.00
 应付分保账款
 保险合同准备金
 代理买卖证券款
 代理承销证券款
 持有待售负债
 一年内到期的非流动负债
 其他流动负债
   流动负债合计                                                 5,880,162,306.86          4,292,573,160.72
非流动负债:
 长期借款                                                       1,273,910,000.00           300,000,000.00
 应付债券                                                       1,497,587,761.33          2,990,994,060.64
 其中:优先股
        永续债
 长期应付款                                                       43,886,381.03             67,159,440.60
 长期应付职工薪酬
 预计负债
 递延收益                                                        483,418,140.53             90,791,520.23
 递延所得税负债
 其他非流动负债
   非流动负债合计                                               3,298,802,282.89          3,448,945,021.47
     负债合计                                                   9,178,964,589.75          7,741,518,182.19
所有者权益(或股东权益)
 实收资本(或股本)                                             3,108,175,038.00          3,108,226,603.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                                       2,136,283,359.43          2,242,451,490.53
 减:库存股                                                       73,449,429.00            199,999,904.37
 其他综合收益
 专项储备
 盈余公积                                                        451,082,066.45            451,082,066.45
 一般风险准备
 未分配利润                                                     3,207,000,977.62          3,503,397,738.27
 归属于母公司所有者权益合计                                     8,829,092,012.50          9,105,157,993.88
 少数股东权益                                                    258,195,521.56            255,238,827.68
   所有者权益(或股东权益)合计                                 9,087,287,534.06          9,360,396,821.56
     负债和所有者权益(或股东权益)总计                     18,266,252,123.81            17,101,915,003.75


  法定代表人:王爱军              主管会计工作负责人:王威                会计机构负责人:王爱玲


                                                10 / 19
                                      2018 年第三季度报告




                                   母公司资产负债表
                                   2018 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司
                                               单位:元 币种:人民币 审计类型:未经审计
                      项目                                  期末余额              年初余额
流动资产:
 货币资金                                                     1,064,482,298.28     934,732,492.98
 以公允价值计量且其变动计入当期损益的金融资产                    33,450,000.00
 衍生金融资产
 应收票据及应收账款                                             219,632,087.61     201,880,897.12
 其中:应收票据                                                  29,853,570.33      62,210,400.00
        应收账款                                                189,778,517.28     139,670,497.12
 预付款项                                                       139,793,138.17     130,162,606.64
 其他应收款                                                   2,286,978,204.13    3,008,966,501.93
 其中:应收利息
        应收股利                                                                   700,000,000.00
 存货                                                            60,049,018.02     157,362,533.74
 持有待售资产
 一年内到期的非流动资产
 其他流动资产                                                   393,358,762.92      11,552,366.84
   流动资产合计                                               4,197,743,509.13    4,444,657,399.25
非流动资产:
 可供出售金融资产                                               165,369,754.00     180,919,754.00
 持有至到期投资
 长期应收款                                                   2,559,959,405.73    3,315,332,818.55
 长期股权投资                                                 6,954,348,612.53    6,134,575,394.00
 投资性房地产
 固定资产                                                       169,642,488.58     179,739,842.99
 在建工程                                                          471,698.11
 生产性生物资产
 油气资产
 无形资产                                                       104,502,706.03     122,723,496.88
 开发支出
 商誉
 长期待摊费用                                                    21,524,556.55      12,096,408.99
 递延所得税资产                                                   1,137,895.29        1,079,295.43
 其他非流动资产
   非流动资产合计                                             9,976,957,116.82    9,946,467,010.84
     资产总计                                                14,174,700,625.95   14,391,124,410.09
流动负债:
 短期借款                                                     1,792,000,000.00    1,430,000,000.00

                                            11 / 19
                                      2018 年第三季度报告



 以公允价值计量且其变动计入当期损益的金融负债
 衍生金融负债
 应付票据及应付账款                                          2,123,452,090.40    1,811,916,306.85
 预收款项                                                     298,636,069.43      214,532,020.94
 应付职工薪酬                                                    9,668,698.71      12,319,802.77
 应交税费                                                        8,229,071.13        9,409,301.99
 其他应付款                                                  1,435,462,770.60     897,745,073.99
 其中:应付利息                                                75,560,177.73       54,511,385.44
       应付股利                                               326,493,672.87       12,037,536.00
 持有待售负债
 一年内到期的非流动负债
 其他流动负债
   流动负债合计                                              5,667,448,700.27    4,375,922,506.54
非流动负债:
 长期借款                                                    1,273,910,000.00     300,000,000.00
 应付债券                                                    1,497,587,761.33    2,990,994,060.64
 其中:优先股
        永续债
 长期应付款                                                    23,886,381.03       47,159,440.60
 长期应付职工薪酬
 预计负债
 递延收益
 递延所得税负债
 其他非流动负债
   非流动负债合计                                            2,795,384,142.36    3,338,153,501.24
     负债合计                                                8,462,832,842.63    7,714,076,007.78
所有者权益(或股东权益)
 实收资本(或股本)                                          3,108,175,038.00    3,108,226,603.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                                    2,102,533,491.84    2,208,701,622.94
 减:库存股                                                    73,449,429.00      199,999,904.37
 其他综合收益
 专项储备
 盈余公积                                                     451,082,066.45      451,082,066.45
 未分配利润                                                   123,526,616.03     1,109,038,014.29
    所有者权益(或股东权益)合计                             5,711,867,783.32    6,677,048,402.31
     负债和所有者权益(或股东权益)总计                     14,174,700,625.95   14,391,124,410.09


法定代表人:王爱军            主管会计工作负责人:王威             会计机构负责人:王爱玲


                                            12 / 19
                                                2018 年第三季度报告



                                                   合并利润表
                                                 2018 年 1—9 月
    编制单位:梅花生物科技集团股份有限公司
                                                          单位:元 币种:人民币 审计类型:未经审计
                                                                              年初至报告期       上年年初至报告
                                    本期金额             上期金额
                 项目                                                       期末金额(1-9 月)   期期末金额(1-9
                                   (7-9 月)            (7-9 月)
                                                                                                      月)
一、营业总收入                    3,012,588,244.35     2,334,579,628.52       9,300,291,532.84    7,940,373,793.70
其中:营业收入                    3,012,588,244.35     2,334,579,628.52       9,300,291,532.84    7,940,373,793.70
       利息收入
       已赚保费
       手续费及佣金收入
二、营业总成本                    2,743,575,398.49     2,287,419,374.06       8,514,561,816.39    7,279,004,858.50
其中:营业成本                    2,233,126,029.17     1,897,558,400.01       7,014,162,991.99    6,000,551,023.81
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金净额
       保单红利支出
       分保费用
       税金及附加                   48,962,310.56         31,563,217.24        162,719,304.99      111,936,717.30
       销售费用                    237,035,642.84        176,384,759.79        718,542,108.71      629,600,543.86
       管理费用                    121,020,223.11        101,818,120.17        354,383,044.24      309,153,403.48
       研发费用                      7,286,128.86          5,841,132.30         20,196,160.14       16,137,770.29
       财务费用                     96,145,063.95         74,203,744.55        242,945,669.73      200,061,907.89
       其中:利息费用               74,069,841.96         67,136,620.74        212,364,704.00      185,671,826.35
                 利息收入            1,495,610.05          1,020,234.79          4,568,778.49        3,610,932.63
       资产减值损失                            0.00             50,000.00        1,612,536.59       11,563,491.87
  加:其他收益                       3,128,072.95          8,379,827.15         35,975,817.07      115,729,657.91
       投资收益(损失以“-”号
                                    12,946,609.57         30,295,374.59         37,816,026.48       60,366,318.81
填列)
       其中:对联营企业和合营
                                      -507,247.44           -133,856.09           -530,659.38         -133,856.09
企业的投资收益
       公允价值变动收益(损失
                                    22,055,000.00          3,807,936.60         25,542,000.00        5,195,914.60
以“-”号填列)
       资产处置收益(损失以
                                        69,575.65          1,584,107.21           -534,280.71        1,766,206.84
“-”号填列)
       汇兑收益(损失以“-”号
填列)
三、营业利润(亏损以“-”号填
                                   307,212,104.03         91,227,500.01        884,529,279.29      844,427,033.36
列)

                                                      13 / 19
                                            2018 年第三季度报告



  加:营业外收入                    5,958,368.23        4,407,574.31     8,342,916.60     9,347,465.35
  减:营业外支出                    3,254,732.24         502,087.91      6,776,010.10    14,164,464.11
四、利润总额(亏损总额以“-”
                                  309,915,740.02       95,132,986.41   886,096,185.79   839,610,034.60
号填列)
  减:所得税费用                   47,616,914.95       16,498,800.18   142,421,216.45   128,320,554.03
五、净利润(净亏损以“-”号填
                                  262,298,825.07       78,634,186.23   743,674,969.34   711,289,480.57
列)
 (一)按经营持续性分类
       1.持续经营净利润(净亏损
                                  262,298,825.07       78,634,186.23   743,674,969.34   711,289,480.57
以“-”号填列)
       2.终止经营净利润(净亏损
以“-”号填列)
 (二)按所有权归属分类
       1.归属于母公司所有者的
                                  259,660,915.61       74,884,081.07   729,301,001.89   695,327,136.24
净利润
       2.少数股东损益               2,637,909.46        3,750,105.16    14,373,967.45    15,962,344.33
六、其他综合收益的税后净额
  归属母公司所有者的其他综合
收益的税后净额
     (一)不能重分类进损益的
其他综合收益
       1.重新计量设定受益计划
变动额
       2.权益法下不能转损益的
其他综合收益
     (二)将重分类进损益的其
他综合收益
       1.权益法下可转损益的其
他综合收益
       2.可供出售金融资产公允
价值变动损益
       3.持有至到期投资重分类
为可供出售金融资产损益
       4.现金流量套期损益的有
效部分
       5.外币财务报表折算差额
  归属于少数股东的其他综合收
益的税后净额
七、综合收益总额                  262,298,825.07       78,634,186.23   743,674,969.34   711,289,480.57
  归属于母公司所有者的综合收
                                  259,660,915.61       74,884,081.07   729,301,001.89   695,327,136.24
益总额
  归属于少数股东的综合收益总
                                    2,637,909.46        3,750,105.16    14,373,967.45    15,962,344.33

                                                   14 / 19
                                                2018 年第三季度报告



八、每股收益:
  (一)基本每股收益(元/股)                    0.08                  0.02                0.23                0.22
  (二)稀释每股收益(元/股)                    0.08                  0.02                0.23                0.22


    本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元, 上期被合并方实现的
    净利润为: 0 元。
    法定代表人:王爱军        主管会计工作负责人:王威        会计机构负责人:王爱玲



                                         母公司利润表
                                        2018 年 1—9 月
    编制单位:梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                                                                            年初至报告期期      上年年初至报告
                                    本期金额             上期金额
                 项目                                                           末金额            期期末金额
                                   (7-9 月)            (7-9 月)
                                                                              (1-9 月)          (1-9 月)
一、营业收入                      1,785,852,639.53     1,398,648,649.36      5,590,409,843.55    4,922,612,594.54
  减:营业成本                    1,606,790,895.19     1,219,180,500.16      4,996,590,661.94    4,325,254,305.43
       税金及附加                    4,037,352.57          3,468,255.98        13,064,349.37       10,719,412.20
       销售费用                    132,857,018.44        110,306,376.95       435,155,831.70      406,483,884.92
       管理费用                     34,842,885.48         32,957,833.71       116,345,830.82       96,618,335.67
       研发费用
       财务费用                     34,536,351.57          3,628,072.74        54,978,510.04        9,621,507.04
       其中:利息费用                6,125,629.50          3,943,219.12        17,476,584.19        8,989,381.35
                 利息收入              403,767.51           482,777.23          1,207,451.67        1,629,577.56
       资产减值损失                                                               390,665.74        9,615,536.51
  加:其他收益                                                                 13,207,322.28       10,963,131.38
       投资收益(损失以“-”号
                                     6,393,615.45         14,255,352.38        23,437,253.62       30,538,132.81
填列)
       其中:对联营企业和合营
企业的投资收益
       公允价值变动收益(损失
                                    22,055,000.00                              33,450,000.00
以“-”号填列)
       资产处置收益(损失以
                                                                -4,559.97                              -22,413.81
“-”号填列)
二、营业利润(亏损以“-”号填
                                     1,236,751.73         43,358,402.23        43,978,569.84      105,778,463.15
列)
  加:营业外收入                     3,160,217.01           909,773.60          3,892,581.41        2,186,115.57
  减:营业外支出                        44,253.65               15,599.00         191,812.38          603,233.25
三、利润总额(亏损总额以“-”
                                     4,352,715.09         44,252,576.83        47,679,338.87      107,361,345.47
号填列)
    减:所得税费用                     652,907.25          3,982,779.69         7,492,974.59        2,633,363.23
四、净利润(净亏损以“-”号填       3,699,807.84         40,269,797.14        40,186,364.28      104,727,982.24

                                                      15 / 19
                                                 2018 年第三季度报告



列)
  (一)持续经营净利润(净亏
                                         3,699,807.84       40,269,797.14           40,186,364.28        104,727,982.24
损以“-”号填列)
  (二)终止经营净利润(净亏
损以“-”号填列)
五、其他综合收益的税后净额
  (一)不能重分类进损益的其
他综合收益
       1.重新计量设定受益计划变
动额
    2.权益法下不能转损益的其
他综合收益
  (二)将重分类进损益的其他
综合收益
       1.权益法下可转损益的其他
综合收益
       2.可供出售金融资产公允价
值变动损益
       3.持有至到期投资重分类为
可供出售金融资产损益
       4.现金流量套期损益的有效
部分
       5.外币财务报表折算差额
六、综合收益总额                         3,699,807.84       40,269,797.14           40,186,364.28        104,727,982.24
七、每股收益:
    (一)基本每股收益(元/股)
    (二)稀释每股收益(元/股)


    法定代表人:王爱军                 主管会计工作负责人:王威                     会计机构负责人:王爱玲



                                      合并现金流量表
                                        2018 年 1—9 月
    编制单位:梅花生物科技集团股份有限公司
                                                单位:元 币种:人民币 审计类型:未经审计
                                                                  年初至报告期期末金额        上年年初至报告期期末
                                项目
                                                                       (1-9 月)                   金额(1-9 月)
    一、经营活动产生的现金流量:
        销售商品、提供劳务收到的现金                                     9,813,322,040.46              8,123,898,133.89
        客户存款和同业存放款项净增加额
        向中央银行借款净增加额
        向其他金融机构拆入资金净增加额
        收到原保险合同保费取得的现金

                                                        16 / 19
                                        2018 年第三季度报告



  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当期损益的金融资
产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还                                                 21,067,339.39      24,022,514.52
  收到其他与经营活动有关的现金                                   29,576,086.39     336,379,548.59
     经营活动现金流入小计                                     9,863,965,466.24    8,484,300,197.00
  购买商品、接受劳务支付的现金                                5,521,318,207.57    5,051,555,208.56
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                                608,544,641.20     564,860,436.66
  支付的各项税费                                                704,149,207.97     574,689,994.22
  支付其他与经营活动有关的现金                                  898,200,373.33    1,023,476,890.83
     经营活动现金流出小计                                     7,732,212,430.07    7,214,582,530.27
       经营活动产生的现金流量净额                             2,131,753,036.17    1,269,717,666.73
二、投资活动产生的现金流量:
  收回投资收到的现金                                             84,450,000.00      96,600,000.00
  取得投资收益收到的现金                                         37,073,845.89      60,477,001.11
  处置固定资产、无形资产和其他长期资产收回的现金净
                                                                    362,734.90         151,600.00

  处置子公司及其他营业单位收到的现金净额                                           300,000,000.00
  收到其他与投资活动有关的现金                                  395,501,072.85
     投资活动现金流入小计                                       517,387,653.64     457,228,601.11
  购建固定资产、无形资产和其他长期资产支付的现金              1,577,521,039.51     414,526,826.17
  投资支付的现金                                                581,609,964.02     401,456,737.49
  质押贷款净增加额
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
     投资活动现金流出小计                                     2,159,131,003.53     815,983,563.66
       投资活动产生的现金流量净额                             -1,641,743,349.89   -358,754,962.55
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  其中:子公司吸收少数股东投资收到的现金
  取得借款收到的现金                                          4,123,407,500.00    2,875,727,000.00
  发行债券收到的现金
  收到其他与筹资活动有关的现金                                  110,828,918.00

                                              17 / 19
                                        2018 年第三季度报告



    筹资活动现金流入小计                                        4,234,236,418.00        2,875,727,000.00
  偿还债务支付的现金                                            4,151,640,000.00        1,990,316,000.00
  分配股利、利润或偿付利息支付的现金                              906,245,854.38        1,017,098,555.92
  其中:子公司支付给少数股东的股利、利润
  支付其他与筹资活动有关的现金                                    196,334,889.23           36,266,395.89
    筹资活动现金流出小计                                        5,254,220,743.61        3,043,680,951.81
      筹资活动产生的现金流量净额                               -1,019,984,325.61         -167,953,951.81
四、汇率变动对现金及现金等价物的影响                               31,201,076.02          -10,149,362.25
五、现金及现金等价物净增加额                                    -498,773,563.31           732,859,390.12
  加:期初现金及现金等价物余额                                  2,251,099,698.34        2,402,880,986.97
六、期末现金及现金等价物余额                                    1,752,326,135.03        3,135,740,377.09


法定代表人:王爱军               主管会计工作负责人:王威               会计机构负责人:王爱玲



                                  母公司现金流量表
                                    2018 年 1—9 月
编制单位:梅花生物科技集团股份有限公司
                                            单位:元 币种:人民币 审计类型:未经审计
                                               年初至报告期期末金额           上年年初至报告期期末金额
                   项目
                                                     (1-9 月)                      (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                           5,958,933,729.49               5,085,857,222.10
  收到的税费返还
  收到其他与经营活动有关的现金                           7,994,041,637.16               2,804,182,282.20
    经营活动现金流入小计                                13,952,975,366.65               7,890,039,504.30
  购买商品、接受劳务支付的现金                           4,946,577,182.34               4,571,199,484.36
  支付给职工以及为职工支付的现金                              63,644,613.36                56,974,710.70
  支付的各项税费                                              80,222,470.04                72,021,174.57
  支付其他与经营活动有关的现金                           6,976,197,445.70               3,699,938,121.40
    经营活动现金流出小计                                12,066,641,711.44               8,400,133,491.03
  经营活动产生的现金流量净额                             1,886,333,655.21                -510,093,986.73
二、投资活动产生的现金流量:
  收回投资收到的现金                                          15,550,000.00                79,600,000.00
  取得投资收益收到的现金                                  723,437,253.62                1,030,543,205.77
  处置固定资产、无形资产和其他长期资产收回
的现金净额
  处置子公司及其他营业单位收到的现金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                  738,987,253.62                1,110,143,205.77
  购建固定资产、无形资产和其他长期资产支付
                                                              33,620,927.84                29,144,361.34
的现金


                                              18 / 19
                                       2018 年第三季度报告



 投资支付的现金                                        1,185,000,000.00                53,000,000.00
 取得子公司及其他营业单位支付的现金净额
 支付其他与投资活动有关的现金
   投资活动现金流出小计                                1,218,620,927.84                82,144,361.34
     投资活动产生的现金流量净额                         -479,633,674.22              1,027,998,844.43
三、筹资活动产生的现金流量:
 吸收投资收到的现金
 取得借款收到的现金                                    2,112,877,500.00              1,230,000,000.00
 发行债券收到的现金
 收到其他与筹资活动有关的现金                            110,828,918.00               289,007,484.20
   筹资活动现金流入小计                                2,223,706,418.00              1,519,007,484.20
 偿还债务支付的现金                                    2,330,000,000.00              1,100,000,000.00
 分配股利、利润或偿付利息支付的现金                      860,277,664.65               999,054,832.22
 支付其他与筹资活动有关的现金                            468,417,693.75                26,000,000.00
   筹资活动现金流出小计                                3,658,695,358.40              2,125,054,832.22
     筹资活动产生的现金流量净额                        -1,434,988,940.40             -606,047,348.02
四、汇率变动对现金及现金等价物的影响                         20,055,471.91                      -1.97
五、现金及现金等价物净增加额                                 -8,233,487.50             -88,142,492.29
 加:期初现金及现金等价物余额                            908,715,785.78              1,071,648,834.22
六、期末现金及现金等价物余额                             900,482,298.28               983,506,341.93


法定代表人:王爱军              主管会计工作负责人:王威               会计机构负责人:王爱玲



4.2 审计报告
□适用 √不适用




                                             19 / 19
数据加载中...
prevnext
手机查看股票